Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells

被引:59
作者
Nishizaki, M
Sasaki, J
Fang, BL
Atkinson, EN
Minna, JD
Roth, JA
Ji, L
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
[3] Univ Texas, SW Med Ctr, Dept Internal Med & Pharmacol, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA
关键词
D O I
10.1158/0008-5472.CAN-04-0195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrations of the tumor suppressor genes FHIT and p53 are frequently associated with a wide range of human cancers, including lung cancer. We studied the combined effects of FHIT and p53 proteins on tumor cell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and on tumor growth in animal models by adenoviral vector-mediated cotransfer of wild-type FHIT and p53 genes. We found that the coexpression of FHIT and p53 synergistically inhibited tumor cell proliferation in NSCLC cells in vitro and suppressed the growth of human tumor xenografts in nude mice. Furthermore, we found that this synergistic inhibition of tumor cell growth corresponded with the FHIT-mediated inactivation of MDM2, which thereby blocked the association of MDM2 with p53, thus stabilizing the p53 protein. Our results therefore reveal a novel molecular mechanism consisting of FHIT-mediated tumor suppression and the interaction of FHIT with other cellular components in the pathways regulating p53 activity. These findings show that combination treatment with synergistic tumor-suppressing gene therapy such as Ad-FHIT and Ad-p53 may be an effective therapeutic strategy for NSCLC and other cancers.
引用
收藏
页码:5745 / 5752
页数:8
相关论文
共 45 条
[1]  
Ashcroft M, 1999, MOL CELL BIOL, V19, P1751
[2]   Regulation of p53 stability [J].
Ashcroft, M ;
Vousden, KH .
ONCOGENE, 1999, 18 (53) :7637-7643
[3]   Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5'''-P-1,P-3-triphosphate hydrolase [J].
Barnes, LD ;
Garrison, PN ;
Siprashvili, Z ;
Guranowski, A ;
Robinson, AK ;
Ingram, SW ;
Croce, CM ;
Ohta, M ;
Huebner, F .
BIOCHEMISTRY, 1996, 35 (36) :11529-11535
[4]  
Brambilla E, 1998, CLIN CANCER RES, V4, P1609
[5]   Checkpoints: How to activate p53 [J].
Caspari, T .
CURRENT BIOLOGY, 2000, 10 (08) :R315-R317
[6]   Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage [J].
Chen, LH ;
Agrawal, S ;
Zhou, WQ ;
Zhang, RW ;
Chen, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :195-200
[7]   Role of FHIT in human cancer [J].
Croce, CM ;
Sozzi, G ;
Huebner, K .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1618-1624
[8]   FHIT gene therapy prevents tumor development in Fhit-deficient mice [J].
Dumon, KR ;
Ishii, H ;
Fong, LYY ;
Zanesi, N ;
Fidanza, V ;
Mancini, R ;
Vecchione, A ;
Baffa, R ;
Trapasso, F ;
During, MJ ;
Huebner, K ;
Croce, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3346-3351
[9]   An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2 [J].
Evans, SC ;
Viswanathan, M ;
Grier, JD ;
Narayana, M ;
El-Naggar, AK ;
Lozano, G .
ONCOGENE, 2001, 20 (30) :4041-4049
[10]   Muir-Torre-like syndrome in Fhit-deficient mice [J].
Fong, LYY ;
Fidanza, V ;
Zanesi, N ;
Lock, LF ;
Siracusa, LD ;
Mancini, R ;
Siprashvili, Z ;
Ottey, M ;
Martin, SE ;
Druck, T ;
McCue, PA ;
Croce, CM ;
Huebner, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (09) :4742-4747